

*Partnering with*

**SERVIER**



**2024**





## Business Development is a **key enabler** of our 2030 ambition



Acquire/license late-stage assets (post PoC) in hemato-oncology and solid tumors targeting high medical needs and well-defined patient populations to reinforce our commercial leadership



Expand our pipeline in oncology and selected neuroscience or immuno-inflammatory diseases with externally sourced research programs and early-stage clinical assets



Unlock the value of our assets through deals such as combination trials, co-development, out-licensing, co-financing, spin-offs...



Enrich our R&D capabilities with innovative technologies through flexible deal structures



## Oncology

### In Licensing

#### Deal types

**Global rights** as a priority or Regional (EU or USA followed by China or Japan)

#### Discovery & Early-Stage Clinical Focus

##### Cancer cell targeting

- Synthetic lethality
- Apoptosis
- Precision oncology
  - Biomarker-defined populations

##### Immuno-oncology

- Tumor immune micro-environment
  - T-cell targeting

#### Late-stage Clinical Focus

- Hematologic tumors (**ALL, AML, MDS**)
- Solid tumors (**GI & CNS** as a priority)

#### Modalities

- Small molecules and biologics (mAbs, bispecifics, ADCs)

### Out Licensing

- Global or Regional
- Co-Development, Research Collaborations

### Global BD



**Valérie Agrapart, PharmD**  
Director, Business Development  
Oncology  
valerie.agrapart@servier.com



**Jérôme Roussel, PharmD**  
Director, Business Development Oncology &  
Diagnostics  
jerome.roussel@servier.com



**Alix Scholer-Dahirel, PharmD**  
Director, Business Development Oncology  
alix.scholer-dahirel@servier.com

### R&D Search & Evaluation



**Irene Blat, PharmD**  
Senior Director, Search & Evaluation,  
Oncology  
irene.blat@servier.com



**Tian Li, PhD**  
Associate Director, Search & Evaluation,  
Asia-Pacific  
tian.li@servier.com

### Local BD



**USA**  
**Pat Fetaya, MBA, MSc**  
Head, US Business Development  
pat.fetaya@servier.com



**Asia**  
**Cynthia Wang, MBA, MSc**  
Director, Business Development Asia-Pacific  
cynthia.wang@servier.com

### Global BD Coordination



**Valérie Coudane**  
GBD Coordination Officer, Oncology  
valerie.coudane@servier.com



## Neuroscience

### Pre-clinical & early-clinical stage

#### Biological mechanisms

Normalizing disease-disrupted mechanisms through modulating the expression and/or activity of targets through direct (increased/reduced protein translation) and indirect (increased/reduced clearance) means

#### Target class

Targeting RNA, proteins and/or pathways causally linked to disease

#### Indications: Rare neurological disorders or well defined sub-populations

Neurodevelopmental, neurodegenerative & neuromuscular disorders:

- Genetically-driven pediatric epilepsies e.g., Rett syndrome, Fragile X syndrome, Angelman syndrome, DEEs...
- Neurodegenerative movement disorders e.g., amyotrophic lateral sclerosis, ataxias, dystrophies...
- Neuroimmunological diseases e.g., myasthenia gravis, inflammatory myopathies...

#### Modalities and drug delivery

- Small molecules, incl. RNA and ion channel targeting
- Oligonucleotides, incl. ASO
- Monoclonal antibodies, including bi-specifics
- Technologies improving delivery and biodistribution to the peripheral and central nervous system

### Global BD



**Jørund Sollid, PhD**  
Global Lead, Neuroscience & Immuno-Inflammation BD  
jorund.sollid@servier.com



**David Theron, PharmD**  
Business Development Project Director  
david.theron@servier.com

### R&D Search & Evaluation



**Camille Nicoleau, PhD**  
Director, Search & Evaluation, Neuroscience  
camille.nicoleau@servier.com



**Tian Li, PhD**  
Associate Director, Search & Evaluation, Asia-Pacific  
tian.li@servier.com

### Local BD



**USA**  
**Pat Fetaya, MBA, MSc**  
Head, US Business Development  
pat.fetaya@servier.com



**Asia**  
**Cynthia Wang, MBA, MSc**  
Director, Business Development Asia-Pacific  
cynthia.wang@servier.com

### Global BD Coordination



**Lara-Maria Matar**  
GBD Coordination Officer, Neuroscience & Immuno-Inflammation  
laramaria.matar@servier.com

## Cardio-Metabolism & Veinous Diseases

### Indications

- Hypertension
- Heart Failure
- Coronary Artery Diseases
- Dyslipidemia
- Diabetes
- Chronic Venous Insufficiency

### Development Stage

- From ongoing phase 3 to Commercial

### Deal Type

- Licensing
- Asset Purchase

### Geographic Scope

- Europe & Row (excl. USA & Japan)

### Global BD

---



**Patrick Lenoir**

**Global Head of BD - CMVD**

patrick.lenoir@servier.com



**Flore Dutreil**

**Director, BD CMVD**

flore.dutreil@servier.com

### Local BD

---

**Asia**



**Cynthia Wang, MBA, MSc**

**Director, Business Development Asia-Pacific**

cynthia.wang@servier.com

### Global BD Coordination

---



**Delphine Duong**

**GBD Coordination Officer, Research Transactions & CMVD**

delphine.duong@servier.com

## Therapeutic modalities & technologies

### Modality development strategies

#### Small Molecules

- Kinase, PPI, Receptor modulators; Molecular Glues, Bifunctional molecules, Small molecule targeting RNA for targeted protein degradation/upregulation
- Targeted delivery: prodrugs/polymer drug conjugates/targeted Lipid Nano Particles, Exosomes, Extracellular Vesicles
- Compound Library

#### Oligonucleotides

- Novel Monomers, Antisense Oligonucleotide (ASO) design technologies, ASO-conjugates and drug delivery systems, targeted saRNA, selective cell ligand targeting for neuronal cell delivery
- Oligo-Manufacturing

#### Antibodies

- Novel Formats: Ab Fragments, Single Domain Antibodies, Bi-/ Multi-specifics, optimized Fc domains
- Novel technology platform for Antibody Hard-to-Drug targets
- Synthetic antibody libraries
- ADCs linkage Chemistry/ Conditionally active antibody format

### AI driven strategy

- AI/ML Data-Driven Platform to support Target ID, Lead Generation & Drug Design Prediction methods for Antibody optimization
- AI/ML for drug repositioning, indication expansion, clinical combinations

### R&D Search & Evaluation



#### Georges Da Violante

Director, Search & Evaluation, Enabling Technologies  
georges.da-violante@servier.com



#### Tian Li, PhD

Associate Director, Search & Evaluation, Asia-Pacific  
tian.li@servier.com

### Global BD Coordination



#### Delphine Duong

GBD Coordination Officer, Research Transactions & CMVD  
delphine.duong@servier.com

## Drug discoveries & development technologies

### Phenotypic cell platforms & 3D models

- iPSCs, patient derived models
- Co-culture models
- Organoids, tumoroids (PDAC, CRC, other solid tumors)
- Organ on a Chip (liver, brain, kidney)

### Protein Sciences

- High throughput functional & stability antibody screening
- Antigen specific Immuno-Oncology assays
- Microfluidic or micro array technology B-cell workflow
- Multi-protein production
- High throughput Mass Spectrometry-based proteomic analysis approach
- Mass Spectrometry target

### Imaging

- High content imaging (tissues/cells) and analysis
- Multimodal platforms - Multiplexing, Spatial multiOmics Strategy, Spatial Phenotypic quantification
- In vivo visualization of antisense oligonucleotides (ASO) biodistribution
- ASO tolerability assays

### Sample Optimization

- Universal sample preparation
- Laser Capture Microdissection
- Single cell analysis ATAC (Assay for Transposase Accessible Chromatin)
- High throughput Mass Spectrometry-based proteomic analysis approach

### Liquid Biopsies

- Circulating tumor DNA (ctDNA) and Methylation assay development
- Circulating Tumor Cells (CTC)
- Exosomes or Extracellular Vesicle extraction from Blood for Biomarker Identification.
- Technology to improve sensitivity
- Computational methods for Next-Generation Sequencing

### Flow Chemistry

- Multistep synthesis
- Photochemistry, Electrochemistry
- Automation of downstream process (quenching, phase separation, distillation)
- Continuous crystallisation/drying/milling
- In line analysis.
- Continuous manufacturing in Pharma



**Georges Da Violante**

Director, Search & Evaluation, Enabling Technologies

[georges.da-violante@servier.com](mailto:georges.da-violante@servier.com)



**Tian Li, PhD**

Associate Director, Search & Evaluation, Asia-Pacific

[tian.li@servier.com](mailto:tian.li@servier.com)



## Assets available for partnering or sale

The following assets have been de-prioritized in our portfolio, and we would welcome a discussion with interested parties:

Asset	Target	Modality	Stage	Therapeutic area
SYM015/S95027	MET receptor	Monoclonal antibody	Phase 2	Oncology
SYM029/ONC0084	CD40 agonist	Monoclonal antibody	Lead optimisation	Oncology
S095043	LILRB1/2	Monoclonal antibody	PCC	Oncology
RHU030	Galectin-3	Monoclonal antibody	Lead optimisation	Immuno-Inflammatory



If interested, please fill in the [on-line form](#) and a member of Global Business Development will respond.



*Partnering with*

**SERVIER**



**2024**